Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity (TiTRE)
Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity
The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. The main questions it aims to answer are:
- Does flexible, symptom-guided titration reduce nausea and vomiting compared with standard per-label titration?
- Does flexible titration achieve weight loss comparable to standard titration?
Researchers will compare standard per-label titration with a click-based, symptom-guided titration approach to assess differences in tolerability and treatment effectiveness.
Participants will:
- Be randomly assigned to standard or flexible tirzepatide titration
- Use a click-based dosing method that allows small dose increases based on tolerability (flexible group)
- Attend study visits over 76 weeks for safety and outcome assessments
This study addresses the lack of evidence for individualized titration strategies in obesity treatment and aims to improve tolerability, adherence, and long-term treatment outcomes.
調査の概要
詳細な説明
Tirzepatide is an effective treatment for obesity, but gastrointestinal adverse events during dose escalation may limit tolerability and adherence. Current labeling recommends a fixed titration schedule that does not account for individual differences in symptom tolerance. Evidence supporting individualized titration strategies in obesity treatment remains limited.
This randomized clinical trial aims to evaluate whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. Participants will be randomly assigned to either standard per-label titration or a flexible, click-based titration approach that allows smaller dose increments based on individual tolerability.
Participants in the standard group will follow the approved fixed dose-escalation schedule, while participants in the flexible group will advance doses according to gastrointestinal symptom severity, with the goal of minimizing nausea and vomiting. All participants will attend study visits over 76 weeks for assessment of weight change, tolerability, safety, and treatment adherence.
This study will compare gastrointestinal tolerability and weight-loss outcomes between titration strategies and aims to inform individualized dosing approaches that may improve adherence and long-term obesity treatment outcomes.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Kuwait City、クウェート、15462
- 募集
- Dasman Diabetes Institute
-
主任研究者：
- Ebaa AlOzairi
-
コンタクト：
- Ebaa S AlOZairi, MD
- 電話番号：3111 22242999
- メール：ebaa.alozairi@dasmaninstitute.org
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adults aged 18 years and older
- A diagnosis of obesity (BMI ≥ 27 kg/m2) at screening with self-reported unsuccessful dietary efforts to lose weight.
- No diagnosis of diabetes mellites.
- Able to understand and sign the consent form
- Able to undergo DEXA scan.
Exclusion Criteria:
1. History of type 1 or type 2 diabetes mellites. 2. Obesity-related:
- A self-reported change in body weight >5 kg (11 lbs) within 90 days before screening irrespective of medical records.
- Treatment with any medication for the indication of obesity within the past 90 days before screening.
- Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening; (2) lap banding, if the band has been removed >1 year before screening; (3) intragastric balloon, if the balloon has been removed >1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening.
Uncontrolled thyroid disease, defined as thyroid stimulating hormone >6.0 mIU/L or <0.4 mIU/L as measured by the central laboratory at screening.
3. Mental health:
- History of major depressive disorder within 2 years before screening.
- Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).
- A Patient Health Questionnaire-9 score of ≥15 at screening.
- A lifetime history of a suicidal attempt.
- Suicidal behavior within 30 days before screening. 4. General safety:
- Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown/unspecified content within 90 days before screening.
- Presence of acute pancreatitis within the past 180 days prior to the day of screening.
- History or presence of chronic pancreatitis.
- Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
- Renal impairment measured as estimated glomerular filtration rate value of <15 mL/min/1.73 m2 as defined by KDIGO 2012 by the central laboratory at screening.
- History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
- Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.
- Subject presently classified as being in New York Heart Association Class IV.
- Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.
- Known or suspected abuse of alcohol or recreational drugs.
- Known or suspected hypersensitivity to trial product(s) or related products.
- Previous participation in this trial. Participation is defined as signed informed consent.
- Participation in another clinical trial within 90 days before screening.
- Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Per-label arm (Control)
Participants receive tirzepatide with dose escalation according to the manufacturer's prescribing information.
|
Tirzepatide is administered by subcutaneous injection once weekly.
Dose escalation follows the manufacturer's prescribing information, with advancement through labeled dose levels at prespecified intervals to the assigned maintenance dose
|
|
実験的：Flexible titration arm (Intervention)
Participants receive tirzepatide administered with a flexible dose escalation schedule.
|
Tirzepatide is administered by subcutaneous injection once weekly.
Dose escalation follows a flexible titration schedule as defined in the study protocol.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR)
時間枠：From enrollment (at baseline) to the end of treatment at 76 weeks.
|
Vomiting episodes per patient will be assessed using the validated Modified Index of Nausea, Vomiting, and Retching (M-INVR). The vomiting component is administered weekly, with scores ranging from 0 (no vomiting) to 4 (severe or frequent vomiting), where higher scores indicate worse outcomes. Vomiting burden will be summarized as:
This approach accounts for differences in treatment duration and follow-up time. |
From enrollment (at baseline) to the end of treatment at 76 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence, frequency, and duration of vomiting assessed using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR)
時間枠：Baseline to Week 76
|
Vomiting is assessed weekly using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR), a validated patient-reported outcome measure. The vomiting subscale score is calculated as the sum of relevant vomiting items, with scores ranging from 0 to 16, where higher scores indicate greater incidence, frequency, and duration of vomiting (worse outcome). |
Baseline to Week 76
|
|
Change in body weight
時間枠：Baseline to Week 76
|
Absolute and percentage change in body weight from baseline.
|
Baseline to Week 76
|
|
Proportion of participants remaining on active study medication
時間枠：Week 76
|
Number of participants continuing to receive active study medication at the end of the trial.
|
Week 76
|
|
Change in glycated hemoglobin (HbA1c)
時間枠：Baseline to Week 76
|
Change in HbA1c from baseline.
|
Baseline to Week 76
|
|
Change in lean body mass assessed by dual-energy X-ray absorptiometry (DEXA)
時間枠：Baseline to Week 76
|
Change in total lean body mass measured by dual-energy X-ray absorptiometry (DEXA).
|
Baseline to Week 76
|
|
Change in visceral adiposity assessed by dual-energy X-ray absorptiometry (DEXA)
時間枠：Baseline to Week 76
|
Change in visceral adipose tissue measured by dual-energy X-ray absorptiometry (DEXA).
|
Baseline to Week 76
|
|
Change in fat body mass assessed by dual-energy X-ray absorptiometry (DEXA)
時間枠：Baseline to Week 76
|
Change in total fat body mass measured by dual-energy X-ray absorptiometry (DEXA).
|
Baseline to Week 76
|
|
Change in Alanine Aminotransferase (ALT)
時間枠：Baseline to Week 76
|
Change from baseline in serum alanine aminotransferase (ALT) levels in U/L, measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Aspartate Aminotransferase (AST)
時間枠：Baseline to Week 76
|
Change from baseline in serum aspartate aminotransferase (AST) levels in U/L, measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Gamma-Glutamyl Transferase (GGT)
時間枠：Baseline to Week 76
|
Change from baseline in serum gamma-glutamyl transferase (GGT) levels in U/L, measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Alkaline Phosphatase (ALP)
時間枠：Baseline to Week 76
|
Change from baseline in serum alkaline phosphatase (ALP) levels in U/L, measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Fibrosis-4 (FIB-4) index
時間枠：Baseline to Week 76
|
Change from baseline in the Fibrosis-4 (FIB-4) index, a composite score calculated as: FIB-4 = (Age × AST) / (Platelet count × √ALT), where age is measured in years, AST and ALT in U/L, and platelet count in 10⁹/L. The FIB-4 index is reported as a unitless value, with higher values indicating greater liver fibrosis. Values typically range from approximately 0 to 10. |
Baseline to Week 76
|
|
Change in Total Cholesterol
時間枠：Baseline to Week 76
|
Change from baseline in fasting total cholesterol levels measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Low-Density Lipoprotein Cholesterol (LDL-C)
時間枠：Baseline to Week 76
|
Change from baseline in fasting low-density lipoprotein cholesterol (LDL-C) levels measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in High-Density Lipoprotein Cholesterol (HDL-C)
時間枠：Baseline to Week 76
|
Change from baseline in fasting high-density lipoprotein cholesterol (HDL-C) levels measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in Triglycerides
時間枠：Baseline to Week 76
|
Change from baseline in fasting triglyceride levels measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in estimated glomerular filtration rate (eGFR)
時間枠：Baseline to Week 76
|
Change from baseline in estimated glomerular filtration rate (eGFR) calculated using a standard equation.
|
Baseline to Week 76
|
|
Change in serum creatinine
時間枠：Baseline to Week 76
|
Change from baseline in serum creatinine measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in urinary microalbumin
時間枠：Baseline to Week 76
|
Change from baseline in urinary microalbumin concentration measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in urine albumin-to-creatinine ratio (ACR)
時間枠：Baseline to Week 76
|
Change from baseline in urine albumin-to-creatinine ratio (ACR) measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in thyroid-stimulating hormone (TSH)
時間枠：Baseline to Week 76
|
Change from baseline in serum thyroid-stimulating hormone (TSH) measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in free thyroxine (free T4)
時間枠：Baseline to Week 76
|
Change from baseline in serum free thyroxine (free T4) measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in interleukin-6 (IL-6)
時間枠：Baseline to Week 76
|
Change from baseline in circulating interleukin-6 (IL-6) concentration measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in interleukin-10 (IL-10)
時間枠：Baseline to Week 76
|
Change from baseline in circulating interleukin-10 (IL-10) concentration measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in interleukin-1 receptor antagonist (IL-1Ra)
時間枠：Baseline to Week 76
|
Change from baseline in circulating interleukin-1 receptor antagonist (IL-1Ra) concentration measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in tumor necrosis factor-alpha (TNF-α)
時間枠：Baseline to Week 76
|
Change from baseline in circulating tumor necrosis factor-alpha (TNF-α) concentration measured using standard laboratory methods.
|
Baseline to Week 76
|
|
Change in health-related quality of life assessed using the 36-Item Short Form Health Survey (SF-36)
時間枠：Baseline to Week 76
|
Health-related quality of life is assessed using the 36-Item Short Form Health Survey (SF-36), a validated patient-reported outcome measure. The SF-36 yields an overall score ranging from 0 to 100, with higher scores indicating better health-related quality of life. |
Baseline to Week 76
|
|
Change in dietary intake patterns
時間枠：Baseline to Week 76
|
Changes in macronutrient composition and total caloric intake assessed using multiple-pass 24-hour dietary recalls.
|
Baseline to Week 76
|
|
Incidence of adverse events and laboratory abnormalities
時間枠：Baseline to Week 76
|
Incidence of treatment-emergent adverse events and clinically significant laboratory abnormalities.
|
Baseline to Week 76
|
|
Change in retinal nerve fiber layer thickness assessed by optical coherence tomography (OCT)
時間枠：Baseline to Week 76
|
Change from baseline in retinal nerve fiber layer thickness measured by optical coherence tomography
|
Baseline to Week 76
|
|
Change in arterial stiffness measured by pulse wave velocity (PWV)
時間枠：Baseline to Week 76
|
Change from baseline in arterial stiffness assessed by carotid-femoral pulse wave velocity.
|
Baseline to Week 76
|
|
Change in sudomotor function assessed by Sudoscan
時間枠：Baseline to Week 76
|
Change from baseline in sudomotor function measured by electrochemical skin conductance using Sudoscan.
|
Baseline to Week 76
|
|
Treatment Persistence and Discontinuation
時間枠：Up to 76 weeks
|
Treatment persistence will be assessed by the proportion of participants remaining on active study medication at week 76.
Treatment discontinuation and reasons for discontinuation will be recorded throughout the study and categorized as gastrointestinal adverse events (including nausea and vomiting), other adverse events, lack of efficacy, participant preference, protocol non-adherence, loss to follow-up, pregnancy, investigator decision, or other specified reasons.
|
Up to 76 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- RA HM-2026-06
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。